Malignant pleural effusion (MPE) accompanying lung adenocarcinoma indicates poor
prognosis and early metastasis. This study aimed to identify genes related to MPE formation …

Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating
consequences. Since vascular endothelial growth factor (VEGF) has been implicated in …

Background VEGF is critical in the pathogenesis of malignant pleural effusion (MPE). To
understand the clinical benefits of antiangiogenic agents, the efficacy of chemotherapy …

Background The approach to palliative treatment of malignant pleural effusion (MPE) should
be individualized because these patients generally have poor survival. Our study aimed to …

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung
cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular …

Background Vascular endothelial growth factor (VEGF) is a critical regulator of malignant
pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and …

To evaluate the efficacy and toxicity of three intrapleural therapy regimens consisting of
bleomycin (BLM), OK-432 (a pulverized product of heat-killed Streptococcus pyogenes) or …

INTRODUCTION The discovery of malignant cells in pleural fluid and/or parietal pleura
signifies disseminated or advanced disease and a reduced life expectancy in patients with …

Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer
(NSCLC) with malignant pleural effusion (MPE), but little is known regarding the efficacy of …

Background Metastasis occurs in a series of discrete steps involving invasion, angiogenesis,
lymphovascular space permeation, and establishment of secondary tumors. Malignant …